Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Center 4:47–53

Article  Google Scholar 

Wyld L, Audisio RA, Poston GJ (2015) The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 12:115–124

Article  PubMed  Google Scholar 

Schaue D, McBride WH (2015) Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 12:527–540

Article  PubMed  PubMed Central  Google Scholar 

Galmarini D, Galmarini CM, Galmarini FC (2012) Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol Italic 84:181–199. https://doi.org/10.1016/j.critrevonc.2012.03.002

Article  Google Scholar 

Stoffel A (2010) Targeted therapies for solid tumors: current status and future perspectives. BioDrugs Italic 24:303–316. https://doi.org/10.2165/11535880-000000000-00000

Article  CAS  Google Scholar 

Baxevanis CN, Perez SA, Papamichail M (2009) Cancer immunotherapy. Crit Rev Clin Lab Sci 46:167–189

Article  PubMed  CAS  Google Scholar 

Li X, Lovell JF, Yoon J, Chen X (2020) Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol 17:657–674

Article  PubMed  Google Scholar 

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

Article  PubMed  Google Scholar 

Boumahdi S, de Sauvage FJ (2020) The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19:39–56. https://doi.org/10.1038/s41573-019-0044-1

Article  PubMed  CAS  Google Scholar 

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389:299–311

Article  PubMed  CAS  Google Scholar 

Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17:147–167

Article  PubMed  Google Scholar 

Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL (2023) Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol Italic 16:40. https://doi.org/10.1186/s13045-023-01436-2

Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical RandD efficiency. Nat Rev Drug Discov Italic 11:191–200. https://doi.org/10.1038/nrd3681

Article  CAS  Google Scholar 

Shao L, Xu L, Li Q, Chakravarthy R, Yang Z, Kaitin KI (2016) Regulatory watch: innovative drug availability in China. Nat Rev Drug Discov Italic 15:739–740. https://doi.org/10.1038/nrd.2016.200]

Article  CAS  Google Scholar 

Zhou Q, Chen XY, Yang ZM, Wu YL (2017) The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol 14:577–583

Article  PubMed  Google Scholar 

The State Council of the People’s Republic of China The State Council of the People’s Republic of China on Reforming the Review and Approval System for Drugs and Medical Devices. https://www.nmpa.gov.cn/yaopin/ypjgdt/20150818200801281.html?type=pc&m=. Accessed 7 May 2024

National Medical Products Administration (2020) Provisions for Drug Registration. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html. Accessed 7 May 2024

National Medical Products Administration (2020) Announcement of the National Medical Products Administration on the Release of Three Documents including the “Trial Work Procedures for the Review of Breakthrough Therapy Drugs” (No. 82 of 2020). https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200708151701834.html. Accessed 25 Aug 2025

Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683

Article  PubMed  CAS  Google Scholar 

Zhao F (2016) Surrogate end points and their validation in oncology clinical trials. J Clin Oncol 34:1436–1437

Article  PubMed  Google Scholar 

U.S. Food & Drug Administration (1992) Accelerated Approval. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval. Accessed 7 May 2024

Center For Drug Evaluation NMPA Center For Drug Evaluation, National Medical Products Administration on the Publication of the Technical Guidelines for Conditional Approval of Drugs for Marketing (for Trial Implementation) (No.41 of 2020). https://www.cde.org.cn/main/news/viewInfoCommon/d1716db06f90c3adf134de337373b22c. Accessed 7 May 2024

National Medical Products Administration Center For Drug Evaluation (1998) Technical guidelines on endpoints in clinical trials of antineoplastic drugs. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=24d174aa6995cf17e7aa12d6aa0317aa. Accessed 7 May 2024

Cooper K, Tappenden P, Cantrell A, Ennis K (2020) A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer Italic 123:1686–1696. https://doi.org/10.1038/s41416-020-01050-w]

Article  Google Scholar 

Gyawali B, Hey SP, Kesselheim AS (2020) Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine Italic 21:100332. https://doi.org/10.1016/j.eclinm.2020.100332

Article  Google Scholar 

AstraZeneca (2021) Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US. https://www.astrazeneca.com/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html#. Accessed 7 May 2024

National Healthcare Security Administration (2023) Public consultation on the Work Programme for the Adjustment of the National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 2023 and related documents. http://www.nhsa.gov.cn/art/2023/6/9/art_113_10781.html. Accessed 7 May 2023

Chinese Society Of Clinical Oncology (2015) Chinese Society of Clinical Oncology Guidelines. https://www.csco.org.cn/cn/ncontent.aspx?oid=8929.Accessed Accessed 7 May 2024

Center For Drug Evaluation NMPA https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d. Accessed 20 May 2024

National Medical Products Administration https://www.nmpa.gov.cn/yaopin/ypjgdt/index.html. Accessed 20 May 2024

Gyawali B, Hey SP, Kesselheim AS (2019) Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med Italic 179:906–913. https://doi.org/10.1001/jamainternmed.2019.0462

Article  Google Scholar 

Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175:1992–1994. https://doi.org/10.1001/jamainternmed.2015.5868

Article  PubMed  Google Scholar 

Cliff ERS, Rome RS, Kesselheim AS, Rome BN (2023) National Comprehensive Cancer Network guideline recommendations of cancer drugs with accelerated approval. JAMA Netw Open Italic 6:e2343285. https://doi.org/10.1001/jamanetworkopen.2023.43285

Article  Google Scholar 

National Comprehensive Cancer Network Development and update of guidelines. https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines. Accessed 24 Sept 2024

Luo X, Du X, Huang L, Guo Q, Lv X, Wang C et al (2023) Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022. EClinicalMedicine Italic 63:102177. https://doi.org/10.1016/j.eclinm.2023.102177

Article  Google Scholar 

National Medical Products Administration (2020) Provisions for drug registration. https://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012.htm. Accessed 7 May 2024

Agrawal S, Arora S, Amiri-Kordestani L, de Claro RA, Fashoyin-Aje L, Gormley N et al (2023) Use of single-arm trials for US food and drug administration drug approval in oncology, 2002–2021. JAMA Oncol 9:266–272

Article  PubMed  Google Scholar 

Center for Drug Evaluation N (2020) Center for drug evaluation on the publication of the technical guidelines for conditional approval of drugs for marketing (for trial implementation) (No. 41 of 2020). https://www.cde.org.cn/main/news/viewInfoCommon/d1716db06f90c3adf134de337373b22c. Accessed 8 October 2024

Center for Drug Evaluation (2023) Technical guidelines on the applicability of single-arm clinical trials for use in support of oncology drug marketing applications. https://www.cde.org.cn/main/news/viewInfoCommon/9f0c25dee6ba6781af809b36cf682eb6. Accessed 30 July 2024

National Medical Products Administration The issuance of the list of typical application scenarios of artificial intelligence for drug supervision and regulation. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20240618144318144.html. Accessed 31 July 2024

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å et al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18:1307–1316

Article  PubMed  CAS  Google Scholar 

Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, et al. (2018) FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist Italic 23:740–5. [https://doi.org/10.1634/theoncologist.2017-0642]

Chinese Society Of Clinical Oncology Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for Non-Small-Cell Lung Carcinoma 2020. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/202011/202011927862.pdf. Accessed 8 Nov 2024

Jia B, Zhao J, Jin B, Zhang F, Wang S, Zhang L et al (2023) 36p prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: a real-world multi-center study. J Thorac Oncol 18:S61. https://doi.org/10.1016/S1556-0864(23)00290-3

Article  Google Scholar 

National Medical Products Administration (2020) Notification of drug approval release on 05 March 2020. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20200305153501704.html. Accessed 8 Nov 2024

Darafenib Mesylate Capsules. https://www.nhsa.gov.cn/attach/Ypsn/YPSN202200138-N2/YPSN202200138-N2(PPT).pdf. Accessed 8 Nov 2024

Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G et al (2022) Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (camel-sq): a phase 3 trial. J Thorac Oncol 17:544–557

Article  PubMed  CAS  Google Scholar 

Chinese Society of Clinical Oncology Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for Non-Small-Cell Lung Carcinoma 2021. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20220106030005.pdf. Accessed 25 Sept 2024

Europe